COLLABORATION TO DEVELOP EVIDENCE-BASED STRATEGIES TO HELP IMPROVE OSTEOARTHRITIS MANAGEMENT Haleon and University of Sydney launch 5-Year fellowship to research efficacy of dietary supplements
SEGMENT
Filmed in Sydney and online | February 2025
INTERVIEWS
Professor David Hunter,
Florance and Cope Chair of Rheumatology
Co-Director Sydney Musculoskeletal Health Flagship,
University of Sydney
Dr Bincy Thampi,
Medical & Scientific Affairs Lead
Haleon ANZ
Osteoarthritis is a leading cause of disability affecting over 2 million Australians, according to Australian Institute of Health and Welfare report on Chronic musculoskeletal conditions (2024) and 595 million people globally, according to BD 2021 Osteoarthritis Collaborators. Global, regional, and national burden of osteoarthritis, 1990–2020. It represents a significant public health burden that diminishes quality of life among ageing populations.
Consumer healthcare company Haleon is sponsoring a five-year named fellowship program at the University of Sydney that will investigate the therapeutic role of supplements in managing osteoarthritis symptoms and digital health technologies that improve mobility.
The fellowship will fund a postdoctoral researcher to work under the guidance of world leading osteoarthritis expert, rheumatologist and researcher Professor David Hunter.
Australian Health Journal spoke with Professor Hunter who said the research collaboration represents a shared focus and investment in improving osteoarthritis management: “This is a disabling disease that has a huge impact on the people affected.”
“A collaborative effort between researchers and manufacturers will drive innovation and hopefully improve the lives of those impacted by this devastating disease. Use of supplements and natural ingredients in managing osteoarthritis is an exciting area with a lot of potential. I’m not aware of any other long-term, five-year projects of this nature that has osteoarthritis as its focus,” said Hunter.
Haleon and the University of Sydney have a shared goal of finding better management strategies for osteoarthritis and developing better outcomes for the people affected.
Dr Bincy Thampi, Medical & Scientific Affairs Lead at Haleon ANZ, also spoke with Australian Health Journal and says, “Haleon has a strong commitment to scientific research that drives innovative self-care and improves consumer health outcomes.”
“This partnership illustrates Haleon’s commitment to advancing trusted science for our products to better everyday health and we’re excited to see where this partnership with University of Sydney leads,” said Dr Thampi.
-
Pharmacy led men’s urological health
Men’s urological needs refer to the medical and surgical conditions that affect the male urinary tract system and reproductive organs.
A urologist can address these concerns, however a pharmacy-led model of care developed by Brad Butt, called Mens Health Downunder has offered an alternative to certain urological needs of the male adult population over the past 10 years.
Australian Health Journal met with Brad to hear about his journey, Mens Health Downunder and the impact the pharmacy-led model of care has had on patient’s urological as well as mental health.
-
Contrasting Population Needs and Alternative Funding Models
Dr Jaspreet Saini is a GP with a decade of experience, practicing in West Pennant Hills and Rooty Hill, New South Wales. He began his medical journey at Monash University, followed by internships and residency at Blacktown Hospital, in Western Sydney. Instead of confining himself to a single specialty, he pursued general practice to explore various facets of medicine.
-
Stronger patient involvement in new medicines
New strategic agreement between Medicines Industry and Government means stronger patient involvement in new medicines.
Medicines Australia has secured a 5-year Strategic Agreement with the Federal Government, centered on earlier patient involvement and influence in the availability of new medicines in Australia.
